Sequent Scientific Limited has informed the Exchange regarding Board meeting held on August 08, 2025.
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SeQuent Scientific's Board, meeting on August 8, 2025, approved its Q1 FY26 (quarter ended June 30, 2025) unaudited results. Consolidated revenue from operations rose to Rs. 4,414.20 million from Rs. 3,902.10 million a year earlier, with profit after tax nearly doubling to Rs. 175.70 million (vs Rs. 90.50 million) and basic EPS of Rs. 0.57 (vs Rs. 0.26). Standalone performance was weaker, with revenue dropping to Rs. 410.70 million from Rs. 576.70 million and standalone PAT falling to Rs. 33.70 million. The Group booked Rs. 12.50 million in exceptional costs related to the ongoing Composite Scheme of Amalgamation involving Viyash Life Sciences, Symed Labs, and other entities, which is still awaiting approvals. SRBC & Co LLP issued an unmodified limited review report on both standalone and consolidated results.
Strong consolidated earnings growth and improving profitability are positive signals, but a sharp standalone revenue decline and pending large amalgamation scheme create mixed sentiment for shareholders. Near-term stock reaction may hinge on progress of the merger approvals and standalone business recovery.